Acute Ischemic Stroke
Conditions
Keywords
Stroke
Brief summary
This observational study aims to investigate the impact of GGCX gene mutations and GGCX levels on stroke prognosis in patients with ischemic stroke, as well as their correlation. The main issues are: What is the relationship and potential mechanism between GGCX gene mutations and their expression levels and the composite prognosis of recurrence, death, and bleeding events in patients with ischemic stroke? Collect blood samples from enrolled ischemic stroke patients for genetic testing, and conduct follow-up visits at 3, 6, and 12 months after discharge to evaluate clinical prognosis outcomes. This will answer questions about the relationship and mechanism between GGCX gene and patient prognosis.
Interventions
COMBINATION_PRODUCTUsually, all enrolled patients with acute ischemic stroke will receive routine medication and/or surgical treatment according to clinical diagnosis and treatment protocols.
The conventional drug therapy includes anticoagulant, antiplatelet, antihypertensive and other drugs. The surgical therapy includes AIS intravenous thrombolysis or endovascular therapy.
Sponsors
Peking University Aerospace Center Hospital
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to 85 Years
Healthy volunteers
Yes
Inclusion criteria
* Inclusion Criteria (1) Inclusion Criteria for Acute Ischemic Stroke Patients: 1. Aged between 18 and 85 years. 2. Diagnosed with ischemic stroke (in accordance with the Chinese Guidelines for Diagnosis and Treatment of Acute Ischemic Stroke 2023, including TOAST etiological/pathogenic subtypes: large-artery atherosclerosis (LAA), cardioembolism (CE), small-artery occlusion (SAO), stroke of other determined etiology (SOE), and stroke of undetermined etiology (SUE)). 3. Acute onset, with symptoms occurring within 72 hours and being the first episode. 4. Voluntary participation with signed informed consent. (2) Inclusion Criteria for Healthy Controls: 1) Healthy control population matched for age, gender, and risk factors (including personal and family history). *
Exclusion criteria
(1)
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Evaluate the recurrence, death, and bleeding events of stroke in the research subjects | Follow up will be conducted at 3 months, 6 months, and 12 months after the patient's discharge, and the main outcome events mentioned above will be evaluated. | Including recurrent ischemic stroke events; Death events include hemorrhagic death, vascular death, and acute myocardial infarction events; Intracranial or other bleeding events (refer to the International Classification of Bleeding Events ICD-10 code). |
Countries
China
Contacts
Primary ContactXia Zhang, PhD
Outcome results
None listed